M&A

Despite a revenue dip, Kelyniam Global slashed its net loss, secured FDA clearance for a breakthrough implant, and rejected a buyout, charting its own course.

Kestrel Group reports soaring fee income from its core business, but a quarterly loss reveals the deep financial drag from its complex merger with Maiden Holdings.

The European FinTech giant plans a new €70M note issue and a tender offer to refinance debt, signaling a major push for financial flexibility and expansion.

With $336M in the bank and three autoimmune drugs advancing, Jade Biosciences lays out a fast-paced timeline for key clinical milestones in 2026 and 2027.

Denver M&A firm SDR Ventures promotes veteran advisor Scott Mitchell, doubling down on its client-centric strategy for entrepreneurs in a competitive market.

Palmer Square Capital BDC reports a drop in 2025 income and asset value but highlights rock-solid credit quality and an optimistic outlook for 2026.

After a massive divestiture, Vistance Networks reports soaring growth, zero debt, and plans a huge special cash distribution to its shareholders.

EPIC Insurance creates a new leadership role for Miranda Rodriguez, a strategic move to scale its real estate practice and challenge market leaders.

Thermon Group's $2.2 billion sale to CECO Environmental faces legal scrutiny, leaving shareholders to question if the offer is fair amid record profits.

Leaving the volatile crypto world behind, Cipher Digital is raising billions to build massive data centers for tech giants like AWS and Google.

Despite a stock dip, Select Water Solutions' major offering signals a strategic push for growth in water recycling, acquisitions, and infrastructure.

Ditching passive holding, Lite Strategy generated $600k from Litecoin options to fund buybacks. Is this the new playbook for corporate crypto finance?

Fresh off its IPO, Lumexa Imaging's leadership heads to key conferences. Here’s what’s at stake as they pitch their growth strategy to investors.

The major CRO acquisition deepens Worldwide's oncology and FSP capabilities, signaling a strategic move in the consolidating clinical research market.

Align Partners launches a major governance overhaul campaign at Dentium, aiming to fix the 'Korea discount' and unlock value at the undervalued market leader.

Partners Capital closes its largest co-investment fund at over $1B, signaling intense investor appetite for direct private equity deals in the middle market.

With major acquisitions complete, Huntington's leadership will face investors to outline their vision for growth amid a complex economic landscape.

Amid rising drug price scrutiny, Red Nucleus acquires an AI-powered consultancy to revolutionize how biopharma proves the value of new medicines.

With surging revenues and a new body contouring system, Apyx Medical heads to the BTIG conference to prove its growth story is here to stay.

In a planned leadership evolution, Daryl Seaton becomes CEO as founder Bill Sowell targets M&A, positioning the RIA for its next chapter of expansion.